Savara says sayonara to pipeline programs, doubles down on Molgradex, cuts staff

Texas-based biotech Savara is killing off much of its pipeline work amid a staffing cull as it sets its focus on troubled lung disease therapy Molgradex.

First up, its pipeline. The biotech said the phase 3 trial of AeroVanc (vancomycin hydrochloride inhalation powder) in cystic fibrosis patients who have methicillin-resistant Staphylococcus aureus lung infection missed its primary endpoint and will now be culled.